BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $BAYN.DE readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05196035-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270410
DTEND;VALUE=DATE:20270411
SUMMARY:FIONA readout (P3) · Bayer $BAYN.DE
DESCRIPTION:A Study to Learn More About How Well the Study Treatment Finere
 none Works\, How Safe it is\, How it Moves Into\, Through\, and Out of the
  Body\, and the Effects it Has on the Body When…\n\nPrimary completion d
 ate: 2027-04-10 (estimated)\nOriginally planned: 2026-06-27 (+9.4 months)\
 nPhase 3 · Cardio-Met · Chronic Kidney Disease\, Proteinuria\nEnrollment
 : 219 · Sites: 132\n\nPrimary completion = last participant's primary-end
 point data collected\; topline results usually follow weeks to months late
 r. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps:/
 /trialsonar.netlify.app/radar.html?nct=NCT05196035\nhttps://clinicaltrials
 .gov/study/NCT05196035
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05196035
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05794906-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:ARASTEP readout (P3) · Bayer $BAYN.DE
DESCRIPTION:A Study to Compare Darolutamide Given With Androgen Deprivation
  Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Pr
 ostate Cancer and Raise of Prostate Specif…\n\nPrimary completion date: 
 2027-07-30 (estimated)\nOriginally planned: 2027-01-29 (+6.0 months)\nPhas
 e 3 · Oncology · Biochemically Recurrent Prostate Cancer\nEnrollment: 98
 5 · Sites: 226\n\nPrimary completion = last participant's primary-endpoin
 t data collected\; topline results usually follow weeks to months later. S
 ponsor-reported\, often an estimate. Not investment advice.\n\nhttps://tri
 alsonar.netlify.app/radar.html?nct=NCT05794906\nhttps://clinicaltrials.gov
 /study/NCT05794906
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05794906
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06452277-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:SOHO-02 readout (P3) · Bayer $BAYN.DE
DESCRIPTION:A Study to Learn More About How Well Sevabertinib Works and How
  Safe it is Compared With Standard Treatment\, in Participants Who Have Ad
 vanced Non-small Cell Lung Cancer (NSCLC) W…\n\nPrimary completion date:
  2027-10-28 (estimated)\nOriginally planned: 2026-06-02 (+16.9 months)\nPh
 ase 3 · Oncology · Advanced Non-small Cell Lung Cancer\, HER2 Mutation\n
 Enrollment: 444 · Sites: 279\n\nPrimary completion = last participant's p
 rimary-endpoint data collected\; topline results usually follow weeks to m
 onths later. Sponsor-reported\, often an estimate. Not investment advice.\
 n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT06452277\nhttps://clin
 icaltrials.gov/study/NCT06452277
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06452277
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
